News

The trial is designed to evaluate multiple objective efficacy measures in order to support the design of the Phase 3 clinical studies. The randomised, double blind, Phase 2b

Elesclomol is a first-in-class investigational drug candidate that triggers programmed cell death in cancer cells by targeting mitochondrial energy production in cancer cells. The trial, which will enroll

The NON outlined Health Canada’s concerns, which are focused mainly on chemistry, manufacturing, and control (CMC) and preclinical toxicology issues. Health Canada has requested additional information on polyglucose

Annual non-GAAP net income and non-GAAP EPS was $4.1bn and $4.54, up 36% and 35%, respectively, compared to 2009. For the fourth quarter, non-GAAP net income and non-GAAP

The Redcar-based firm intends to use the funds to accelerate the development of a pioneering probe that monitors bio-processes using cells, or parts of them to make medicines

The Prelude SkinPrep System is a transdermal drug delivery system designed as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals Echo anticipates that the

The latest ENLIGHTEN release contains numerous enhancements such as expanded reporting capabilities that provide users with superior report creation flexibility and increased data visibility. The enhancements also include

Allergan will receive a CA$500,000 upfront payment from BLS which will be followed by subsequent additional payments based on net sales. Valeant Pharmaceuticals is a specialty pharmaceutical company

The research, conducted using Thermo Scientific mass spectrometers, provides insight into key areas of stroke evaluation and treatment. The collaboration between the BRIMS Center and Harvard University has